Novo Seeds invests in Dutch biotech firm with NASH focus again
For the third time, Novo Holding's venture arm Novo Seeds has invested in biotech company Northsea Therapeutics. This will allow the latter to start a phase III study of a candidate within NASH and continue phase I and II studies of other candidates.
by albert rønning-andersson, translated by catherine brett
Novo Seeds, the department of Novo Holdings which works with early investments, has expressed confidence in Northsea Therapeutics by investing in it for the third time.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.